ArticleBMJ open2025

Evaluating the effects of liraglutide, empagliflozin and linagliptin on mild cognitive impairment remission in patients with type 2 diabetes (LIGHT-MCI): study protocol for a multicentre, randomised controlled trial with an extension phase.

Congcong Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.